2102-2103 / 2351
BERIL-1 Key Secondary Endpoint: Overall Survival
June 5,
2016
Soulières D
et al.
ASCO
2016:Abstract 6008
Number of patients at risk
79
79
67
68
60
55
54
40
44
30
39
25
26
21
20
14
12
10
7
7
6
4
2
3
Buparlisib
Placebo
Time (months)
100
80
60
40
20
0
Probability of overall survival (%)
12-month OS rate:
43%
vs
33%
1
3
1
1
0
0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
Protocol-specified criteria for success were:
HR
≤0.77 and posterior probability of (HR <1) >90.0%